TCGX Acquisition agrees to combine with TriGemX Bio

• TriGemX Bio will merge with TCGX Acquisition, creating a publicly traded company valued at approximately $600 million, assuming no redemptions.
• Expected gross proceeds total approximately $246 million: $86 million from trust funds and $160 million from PIPE common stock financing at $10/share.
• The combined company will trade on Nasdaq as TGEM; TriGemX shareholders will retain 100% of their equity investment without receiving cash.
• Proceeds will fund elismetrep’s Phase 3 migraine trials, a regulatory application, a migraine prevention trial and preparations for a potential US launch.
• Closing is expected in the first quarter of 2027, subject to both companies’ shareholder approvals and customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TCGX Acquisition Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261019182401) on October 19, 2026, and is solely responsible for the information contained therein.